SCHEMBL31549705

SCHEMBL31549705

CC(C)(C)OC(=O)N1CCC(=O)C(c2ccc(C#N)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.50
AR P10275 1/20 0.44
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
EGLN2 Q96KS0 1/20 0.41
NR1H2 P55055 1/20 0.40
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
ESR2 Q92731 1/20 0.39
ALK Q9UM73 1/20 0.39
PDE4B Q07343 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483494 0.84 RORC (0.47) GPR119DDB1CRBNNR1H2MEN1
SCHEMBL1617581 0.84 RORC (0.48) GPR119DDB1CRBNNR1H2JAK2
SCHEMBL31649176 0.83 USP30 (0.43) GPR119DDB1CRBNNR1H2JAK2
SCHEMBL18930521 0.82 GPR119 (0.56) GPR119ARDDB1CRBNJAK2
SCHEMBL26129251 0.82 HTT (0.44) GPR119DDB1CRBNNR1H2MEN1
SCHEMBL30988646 0.82 HTT (0.44) GPR119DDB1CRBNNR1H2MEN1
SCHEMBL27211314 0.82 GRM1 (0.44) GPR119DDB1CRBNNR1H2ESR2
SCHEMBL21344401 0.81 GPR119 (0.52) GPR119AREGLN2JAK2MEN1
SCHEMBL5160786 0.79 DDB1 (0.46) GPR119DDB1CRBNNR1H2ESR2
SCHEMBL31478622 0.79 DDB1 (0.41) GPR119DDB1CRBNNR1H2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025130765-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2025-06-26 WO disclosed
WO-2025068951-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2025-04-03 WO disclosed